Enumeral Biomedical Holdings Inc.
Taking checkpoint inhibition to the next level
This article was originally published in Start Up
Executive Summary
Checkpoint inhibitors have caused a sensation in oncology in recent years, but biotech Enumeral Biomedical Holdings Inc. is setting its sights on the Achilles' heel of the new antibodies – the high failure rate – using a discovery platform that employs cells from human biopsies, rather than more commonly used rodent models.
You may also be interested in...
Keeping Track: Venclexta Approved; Opdivo, Atezolizumab Seek Additional Indications
The latest drug development news and highlights from our FDA Performance Tracker.
Video: Enumeral Aspires To Take PD-1 Inhibition To The Next Level
In an interview at the recent Biotech Showcase, CEO Arthur Tinkelenberg explains his company’s approach to developing the next generation of checkpoint inhibitors.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.